Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Conditions
- Cervical Adenocarcinoma
- Cervical Adenosarcoma
- Cervical Adenosquamous Carcinoma
- Cervical Carcinosarcoma
- Cervical Squamous Cell Carcinoma
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Mucinous Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Undifferentiated Carcinoma
- Fallopian Tube Adenocarcinoma
- Fallopian Tube Carcinosarcoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Squamous Cell Carcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- Malignant Female Reproductive System Neoplasm
- Malignant Ovarian Clear Cell Tumor
- Malignant Ovarian Endometrioid Tumor
- Malignant Ovarian Epithelial Tumor
- Malignant Ovarian Mucinous Tumor
- Malignant Peritoneal Neoplasm
- Malignant Solid Neoplasm
- Ovarian Carcinosarcoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Primary Peritoneal Carcinosarcoma
- Primary Peritoneal Clear Cell Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Primary Peritoneal Transitional Cell Carcinoma
- Primary Peritoneal Undifferentiated Carcinoma
- Unresectable Melanoma
- Uterine Corpus Carcinosarcoma
Interventions
- BIOLOGICAL: Bevacizumab
- OTHER: Laboratory Biomarker Analysis
- DRUG: Nab-paclitaxel
- OTHER: Pharmacological Study
Sponsor
Mayo Clinic